Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 1083

2.
3.

Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.

Yu C, Rahmani M, Almenara J, Subler M, Krystal G, Conrad D, Varticovski L, Dent P, Grant S.

Cancer Res. 2003 May 1;63(9):2118-26.

5.
8.
9.

Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.

Nguyen TK, Rahmani M, Gao N, Kramer L, Corbin AS, Druker BJ, Dent P, Grant S.

Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2239-47.

10.
11.
13.

A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2.

Dai Y, Rahmani M, Corey SJ, Dent P, Grant S.

J Biol Chem. 2004 Aug 13;279(33):34227-39. Epub 2004 Jun 2.

14.

MEK1/2 inhibitors sensitize Bcr/Abl+ human leukemia cells to the dual Abl/Src inhibitor BMS-354/825.

Nguyen TK, Rahmani M, Harada H, Dent P, Grant S.

Blood. 2007 May 1;109(9):4006-15. Epub 2007 Jan 11.

15.

BCR/ABL kinase inhibition by imatinib mesylate enhances MAP kinase activity in chronic myelogenous leukemia CD34+ cells.

Chu S, Holtz M, Gupta M, Bhatia R.

Blood. 2004 Apr 15;103(8):3167-74. Epub 2003 Dec 11.

16.

In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.

Kindler T, Breitenbuecher F, Kasper S, Stevens T, Carius B, Gschaidmeier H, Huber C, Fischer T.

Leukemia. 2003 Jun;17(6):999-1009.

PMID:
12764361
17.

Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.

Parmar S, Katsoulidis E, Verma A, Li Y, Sassano A, Lal L, Majchrzak B, Ravandi F, Tallman MS, Fish EN, Platanias LC.

J Biol Chem. 2004 Jun 11;279(24):25345-52. Epub 2004 Mar 31.

19.

Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro.

Mow BM, Chandra J, Svingen PA, Hallgren CG, Weisberg E, Kottke TJ, Narayanan VL, Litzow MR, Griffin JD, Sausville EA, Tefferi A, Kaufmann SH.

Blood. 2002 Jan 15;99(2):664-71.

20.

Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.

Lee YL, Chen CW, Liu FH, Huang YW, Huang HM.

PLoS One. 2013 Apr 17;8(4):e61939. doi: 10.1371/journal.pone.0061939. Print 2013.

Supplemental Content

Support Center